Should I buy or sell Bio-Path stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares. View BPTH analyst ratings or view top-rated stocks .

How have BPTH shares performed in 2023?

Bio-Path's stock was trading at $1.51 at the beginning of 2023. Since then, BPTH stock has decreased by 69.5% and is now trading at $0.4603. View the best growth stocks for 2023 here .

Are investors shorting Bio-Path?

Bio-Path saw a decrease in short interest in November. As of November 15th, there was short interest totaling 695,700 shares, a decrease of 28.2% from the October 31st total of 969,600 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is presently 0.3 days. View Bio-Path's Short Interest .

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our BPTH earnings forecast .

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. During the same quarter last year, the company earned ($0.49) EPS.

When did Bio-Path's stock split?

Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA) , Palatin Technologies (PTN) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Amarin (AMRN) , Trevena (TRVN) , Energy Transfer (ET) , Anavex Life Sciences (AVXL) and Biocept (BIOC) .

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by many different retail and institutional investors. Top institutional investors include Walleye Capital LLC (1.69%). View institutional ownership trends .

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Bio-Path Stock Price, News & Analysis (NASDAQ:BPTH)

$0.46

0.00 (0.00%)

(As of 11/28/2023 ET)

Compare

Today's Range: $0.45
▼
$0.47
50-Day Range: $0.36
▼
$0.75
52-Week Range: $0.32
▼
$2.35

Volume: 60,128 shs
Average Volume: 863,806 shs
Market Capitalization: $5.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Bio-Path MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
5.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.62
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.67) to ($1.04) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Bio-Path.

4.0

Short Interest

Percentage of Shares Shorted
5.63% of the outstanding shares of Bio-Path have been sold short.
Short Interest Ratio / Days to Cover
Bio-Path has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Path has recently decreased by 28.25%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bio-Path does not currently pay a dividend.
Dividend Growth
Bio-Path does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPTH.

3.1

News and Social Media Coverage

News Sentiment
Bio-Path has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Bio-Path this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for BPTH on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Path insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.92% of the stock of Bio-Path is held by insiders.
Percentage Held by Institutions
Only 5.74% of the stock of Bio-Path is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bio-Path are expected to grow in the coming year, from ($1.67) to ($1.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Path is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Path is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Path has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bio-Path Stock (NASDAQ:BPTH)

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BPTH Stock News Headlines

November 25, 2023 | americanbankingnews.com

Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

November 20, 2023 | finance.yahoo.com

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 18, 2023 | money.usnews.com

Bio-Path Holdings Inc

November 15, 2023 | finanznachrichten.de

Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2023 Financial Results

November 15, 2023 | msn.com

Bio-Path GAAP EPS of -$0.32 beats by $0.02

November 15, 2023 | benzinga.com

Bio-Path Hldgs: Q3 Earnings Insights

November 15, 2023 | finance.yahoo.com

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 14, 2023 | benzinga.com

Preview: Bio-Path Holdings's Earnings

November 8, 2023 | finance.yahoo.com

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

October 24, 2023 | finance.yahoo.com

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

October 13, 2023 | seekingalpha.com

GRI Bio to sell 4.13M shares for holders

October 13, 2023 | seekingalpha.com

BPTH, HARP and BTDR among mid-day movers

October 13, 2023 | benzinga.com

What's Going On With Bio-Path Holdings Stock?

October 4, 2023 | businesswire.com

Digbi Health Unveils GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1-based Personalized Care for Obesity

September 10, 2023 | finance.yahoo.com

Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit Outlook

September 8, 2023 | finance.yahoo.com

Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 30, 2023 | finance.yahoo.com

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23

August 15, 2023 | finanznachrichten.de

Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Second Quarter 2023 Financial Results

August 15, 2023 | finance.yahoo.com

Bio-Path Holdings Reports Second Quarter 2023 Financial Results

August 14, 2023 | benzinga.com

Bio-Path Holdings's Earnings Outlook

August 8, 2023 | finance.yahoo.com

Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023

August 3, 2023 | seekingalpha.com

Bio-Path prices 3.5M shares at $0.60 in public offering

August 3, 2023 | benzinga.com

Why Bio-Path Holdings (BPTH) Stock Is Down 45%

August 3, 2023 | finance.yahoo.com

Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering

August 1, 2023 | msn.com

Bio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid Leukemia

See More Headlines

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BPTH
CUSIP: N/A
CIK: 1133818
Web: www.biopathholdings.com
Phone: (832) 742-1357
Fax: N/A
Employees: 10
Year Founded: 2007

Profitability

EPS (Most Recent Fiscal Year): ($2.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,870,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -216.18%
Return on Assets: -172.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.54
Quick Ratio: 3.54

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.98 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 12,350,000
Free Float: 11,992,000
Market Cap: $5.68 million
Optionable: Not Optionable
Beta: 1.11

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Peter H. Nielsen MBA (Age 74)
Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
Comp: $722.68k
Mr. Douglas P. Morris (Age 67)
Co-Founder, Director of Investor Relations, Secretary & Director
Comp: $110.68k
Mr. Anthony Price
Senior Vice President of Finance, Accounting & Administration
Dr. Ana Tari Ashizawa Ph.D.
MBA, Senior Vice President of Research, Development & Clinical Design

Key Competitors

View All Competitors

Institutional Ownership

Walleye Capital LLC
Bought 209,238 shares on 11/21/2023
Ownership: 1.694%

View All Institutional Transactions

BPTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings or view top-rated stocks.
How have BPTH shares performed in 2023?: Bio-Path's stock was trading at $1.51 at the beginning of 2023. Since then, BPTH stock has decreased by 69.5% and is now trading at $0.4603.
View the best growth stocks for 2023 here.
Are investors shorting Bio-Path?: Bio-Path saw a decrease in short interest in November. As of November 15th, there was short interest totaling 695,700 shares, a decrease of 28.2% from the October 31st total of 969,600 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is presently 0.3 days.
View Bio-Path's Short Interest.
When is Bio-Path's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BPTH earnings forecast.
How were Bio-Path's earnings last quarter?: Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. During the same quarter last year, the company earned ($0.49) EPS.

When did Bio-Path's stock split?: Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Bio-Path own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).
Who are Bio-Path's major shareholders?: Bio-Path's stock is owned by many different retail and institutional investors. Top institutional investors include Walleye Capital LLC (1.69%).
View institutional ownership trends.
How do I buy shares of Bio-Path?: Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BPTH) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial